1 – 27 of 27
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Replacement therapy during surgery in von Willebrand disease needs personalization
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Evaluation of prophylactic therapy in haemophilia with global coagulation tests
(
- Contribution to journal › Letter
-
Mark
Defining extended half-life rFVIII-A critical review of the evidence
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis : Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network
(
- Contribution to journal › Article
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
-
Mark
Fifth Åland Island conference on von Willebrand disease
(
- Contribution to journal › Article
- 2017
-
Mark
If you know you will also see : Population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Preference-based valuation of treatment attributes in haemophilia A using web survey
(
- Contribution to journal › Article
-
Mark
Low agreement between fresh and frozen-thawed platelet-rich plasma in the calibrated automated thrombogram assay
(
- Contribution to journal › Article
-
Mark
Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy : The Malmö experience
(
- Contribution to journal › Article
-
Mark
Comparative burden of arthropathy in mild haemophilia : a register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
The association between health utility and joint status among people with severe haemophilia A : findings from the KAPPA register
(
- Contribution to journal › Article
-
Mark
Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics
(
- Contribution to journal › Article
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
- 2016
-
Mark
Haemophilia treatment in 2030
(
- Contribution to journal › Article
-
Mark
Registry-based outcome assessment in haemophilia : a scoping study to explore the available evidence
(
- Contribution to journal › Article
-
Mark
Phenotype and genotype comparisons in carriers of haemophilia A
(
- Contribution to journal › Article
-
Mark
Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe
(
- Contribution to journal › Article
-
Mark
Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined.
2016) In Haemophilia(
- Contribution to journal › Article
- 2001
-
Mark
Symposium in memory of Professor Inga Marie Nilsson
(
- Contribution to journal › Published meeting abstract
- 1997
-
Mark
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis
(
- Contribution to journal › Article
-
Mark
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
(
- Contribution to journal › Article
- 1994
-
Mark
Prophylactic treatment of severe hemophilia A and B can prevent joint disability
(
- Contribution to journal › Article
-
Mark
Myocardial infarction associated with homozygous resistance to activated protein C
(
- Contribution to journal › Letter
- 1992
-
Mark
Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia
(
- Contribution to journal › Article
- 1990
-
Mark
Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate
(
- Contribution to journal › Article